Celldex Therapeutics, Inc. Share Price Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 262.24Cr 229.48Cr 212.08Cr 197.94Cr 371.18Cr 25TCr 374.74Cr 2.52TCr 979.81Cr 12TCr 984.51Cr 963.11Cr 42TCr | P/E 2026 * |
-7.7x | P/E 2027 * | -7.65x |
|---|---|---|---|---|---|
| Enterprise Value | 203.83Cr 178.37Cr 164.84Cr 153.85Cr 288.5Cr 19TCr 291.27Cr 1.96TCr 761.57Cr 9.47TCr 765.22Cr 748.59Cr 33TCr | EV / Sales 2026 * |
774x | EV / Sales 2027 * | 177x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.82% | +992.89% | - | - | 254.55Cr | |
| +0.34% | +2.06% | -10.67% | -5.26% | 4.31TCr | |
| +1.73% | +7.76% | +318.08% | +543.17% | 3.47TCr | |
| +0.61% | +2.77% | +10.00% | +46.44% | 3TCr | |
| +0.02% | -7.52% | +8.45% | -21.52% | 2.8TCr | |
| -1.06% | -2.60% | +9.08% | +21.51% | 2.44TCr | |
| -1.23% | +4.56% | - | - | 1.43TCr | |
| -0.99% | -2.50% | +47.29% | +106.70% | 1.31TCr | |
| +1.54% | -0.94% | +6.69% | +8.40% | 1.25TCr | |
| +2.39% | +3.57% | +102.86% | +83.89% | 1.22TCr | |
| Average | +1.42% | +0.65% | +61.47% | +97.92% | 2.36TCr | |
| Weighted average by Cap. | +0.53% | +1.19% | +67.04% | +113.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 26.35L 23.06L 21.31L 19.89L 37.29L 25Cr 37.65L 2.53Cr 98.44L 12Cr 98.91L 96.76L 43Cr | 1.2Cr 1.05Cr 96.74L 90.29L 1.69Cr 113.25Cr 1.71Cr 12Cr 4.47Cr 56Cr 4.49Cr 4.39Cr 193.28Cr |
| Net income | -33Cr -29Cr -27Cr -25Cr -47Cr -3.12TCr -47Cr -317.42Cr -123.32Cr -1.53TCr -123.91Cr -121.22Cr -5.33TCr | -37Cr -32Cr -30Cr -28Cr -52Cr -3.51TCr -53Cr -356.3Cr -138.43Cr -1.72TCr -139.09Cr -136.07Cr -5.99TCr |
| Net Debt | -58Cr -51Cr -47Cr -44Cr -83Cr -5.53TCr -83Cr -561.75Cr -218.24Cr -2.71TCr -219.29Cr -214.52Cr -9.44TCr | -51Cr -44Cr -41Cr -38Cr -72Cr -4.8TCr -73Cr -487.96Cr -189.58Cr -2.36TCr -190.48Cr -186.34Cr -8.2TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
